Suicidal ideation covaries with depressive severity during six-month real-world esketamine treatment in a cohort enriched for borderline personality disorder.
Journal of Affective Disorders August 20, 2026 DOI: 10.1016/j.jad.2026.122405 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | Patients receiving real-world esketamine treatment, enriched for borderline personality disorder |
| Intervention | Esketamine |
| Duration | Six months |
| Topics | Depression Esketamine |
| Key findings | Suicidal ideation covaried with depressive severity over six months of esketamine treatment, suggesting that improvements in suicidal ideation track with improvements in depression in this cohort enriched for borderline personality disorder. |
Abstract
Suicidal ideation covaries with depressive severity during six-month real-world esketamine treatment in a cohort enriched for borderline personality disorder.
Comparable studies
Other observational and cohort studies on esketamine, most cited first.
Citations in the library
Cites 4
- The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis American Journal of Psychiatry October 3, 2017
- Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm. Asian Journal of Psychiatry June 1, 2026
- Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study. Psychiatry Research June 16, 2026
- Is there an independant anti-suicidal effect of esketamine in treatment resistant depression? Journal of Affective Disorders May 1, 2026